|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2005-10-17
|
|
pubmed:abstractText |
The pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) impairs insulin action in insulin-sensitive tissues, such as fat, muscle and endothelium, and causes endothelial dysfunction. We hypothesized that TNF-alpha blockade with etanercept could reverse vascular and metabolic insulin resistance.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1018-1172
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
42
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
517-25
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16155368-Adult,
pubmed-meshheading:16155368-Biological Markers,
pubmed-meshheading:16155368-C-Reactive Protein,
pubmed-meshheading:16155368-Diabetes Mellitus, Type 2,
pubmed-meshheading:16155368-Female,
pubmed-meshheading:16155368-Glucose Tolerance Test,
pubmed-meshheading:16155368-Humans,
pubmed-meshheading:16155368-Immunoglobulin G,
pubmed-meshheading:16155368-Inflammation,
pubmed-meshheading:16155368-Insulin Resistance,
pubmed-meshheading:16155368-Insulin-Secreting Cells,
pubmed-meshheading:16155368-Interleukin-6,
pubmed-meshheading:16155368-Male,
pubmed-meshheading:16155368-Middle Aged,
pubmed-meshheading:16155368-Obesity,
pubmed-meshheading:16155368-Receptors, Tumor Necrosis Factor,
pubmed-meshheading:16155368-Tumor Necrosis Factor-alpha,
pubmed-meshheading:16155368-Vasodilation
|
|
pubmed:articleTitle |
Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes.
|
|
pubmed:affiliation |
Cardiology Department, Research Unit, Bispebjerg University Hospital, Copenhagen, Denmark. hd@heart.dk
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
